Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Left Main Coronary Artery PCI Using State-of-the-Art Zotarolimus-Eluting Stents

Percutaneous coronary intervention (PCI) to the left main coronary artery (LMCA) with drug-eluting stent implantation is currently a major challenge due to the size of the vessel, the compromise of a bifurcation lesion in important branches, and the potential risk of complications.

Angioplastia al tronco de la coronaria izquierda con el uso de stents liberadores de Zotarolimus de última generación

Available information on LMCA PCI comes from studies where DES stents were implanted without the scaffold corresponding to the vessel size and with limited expansion capacity. The new generation of Resolute-Onyx stents includes devices with diameters of 3.5-4.0 mm, expandable to 5.0 mm, and devices with diameters of 4.5-5.0 mm, expandable to 6.0 mm. These devices were designed to optimize the treatment of large bore arteries, such as the LMCA.

The aim of this prospective, multicenter study was to evaluate the results obtained using Resolute Onyx DES in LMCA PCI.

The primary endpoint (PEP) was treated lesion failure (TLF), defined as a composite of cardiac death, target vessel myocardial infarction (TVMI), and ischemia-driven treated lesion revascularization (ID-TLR) at 1 year. The secondary endpoint (SEP) was all-cause mortality, TVMI, ID-TLR, periprocedural acute myocardial infarction, stroke, and stent thrombosis at 30 days and 1 year.

Read also: Can We Use DAPT for 3 Months in Acute Coronary Syndrome?

The study enrolled 450 patients. Mean patient age was 71 years old, and most subjects were male. The most frequent clinical indication was acute coronary syndrome (53%), and 15% of patients were functional class III-IV. The mean SYNTAX score was 24.5, and 10% of patients had LMCA disease only.

Most patients with LMCA disease presented bifurcation lesions (78%), and a lower number had ostial disease (20%). Transradial access was the most common. In 77% of cases, the one-stent technique was the most common, while the two-stent technique was used in the remaining cases. Intravascular imaging was used in 45% of cases (42%, intravascular ultrasound [IVUS]; 3%, optical coherence tomography [OCT]).

In terms of the PEP at 1 year, the cardiac death rate was 2.7%; TVMI, 2.7%, and ID-TLR, 2.0%. The stent thrombosis rate was 1.1%. In an adjusted sub-analysis, patients who underwent IVUS/OCT-guided PCI had a lower incidence of the PEP (2.0 vs. 7.6%; hazard ratio: 0.28; 95% confidence interval: 0.13-0.58; p < 0,001).

Conclusion 

In this prospective study of LMCA PCI using the Resolute Onyx stent, the 1-year incidence of TLF was low, suggesting these devices are safe and efficient for these procedures. When compared with angiographically-guided PCI, using IVUS/OCT was associated with clinical benefit. Randomized studies are needed to confirm these findings.

Dr. Andrés Rodríguez

Dr. Andrés Rodríguez.
Member of the editorial board of SOLACI.org.

Original Title: A large, prospective, multicentre study of left main PCI using a latest-generation zotarolimus-eluting stent: the ROLEX study.

Reference: Giuseppe Tarantini MD et al. EuroIntervention 2022;18.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...